INFORMAZIONI SU QUESTO EPISODIO
Guest: John Cho, MD, PhD, FRCPC
Could lower doses of radiation help optimize immune response in mesothelioma? Dr. John Cho joins us to explain how tailoring radiation to a tumor’s inflammatory and immunogenic characteristics could help modulate antitumor immunity while reducing the potential for fibrosis and treatment-related toxicity. Dr. Cho is a radiation oncologist at the Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto, and he spoke about this topic at the 2026 World Conference on Lung Cancer.
Inglese
Stati Uniti
TRASCRIZIONE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di Project Oncology®.
ALTRI EPISODI IN QUESTO PODCAST
Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Even well-intentioned conversations about tobacco use can leave patients feeling judged and potentially less willing to engage in lung cancer screening, follow-up, or cessation support. Tune in as Dr. Lisa Carter-Bawa shares prac…
Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
For patients who smoke or have a history of smoking, seeking lung cancer screening can mean confronting more than the fear of a diagnosis; it can also mean anticipating blame and judgment. Dr. Lisa Carter-Bawa joins us to share h…
Guest: Jonathon B. Cohen, MD, MS
As chemotherapy-free approaches for mantle cell lymphoma continue to evolve, important questions remain about how best to incorporate them into clinical practice. Here to help shed light on the key unknowns surrounding patient selection, treatment sequenc…
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Krina Patel, MD, MSc
A recent analysis used matching-adjusted indirect comparisons to evaluate anitocabtagene autoleucel, teclistamab, and talquetamab for relapsed or refractory (R/R) multiple myeloma, drawing on data from the iMMAGINE-…
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Krina Patel, MD, MSc
As CAR T-cell therapy options expand for relapsed or refractory (R/R) multiple myeloma, comparative data may help clinicians weigh efficacy and safety when selecting treatment. One recent matching-adjusted indirect …
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da ReachMD, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
